VANCOUVER, BC / August 9th, 2018 / CVR Medical Corp. (CVM.V) (TSXV: CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF)  (“CVR Medical”) a Canadian listed and US based healthcare company in the medical device sector has retained the services of NYC based Investor Relations Public Relations Firm ICR (www.icrinc.com) to support the company’s communications and marketing activities as it explores a US National Market listing and advances toward regulatory submission for its Carotid Stenotic Scan (CSS) device in the U.S.

Established in 1998, ICR partners with companies to optimize transactions and execute strategic communications programs that achieve business goals, build credibility and enhance long-term enterprise value. The firm’s highly differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 500 clients in approximately 20 industries. With headquarters in Norwalk, CT, ICR is one of the largest and most experienced independent communications and advisory firms in North America maintaining offices in New York, Boston, San Francisco, Los Angeles, and Beijing. ICR Healthcare is a specialty practice within ICR that provides communications counsel and support for the firm’s growing portfolio of clients in the biopharmaceutical, MedTech, HCIT and healthcare services sectors.

CVR Medical Chief Executive Officer Peter Bakema stated, “As we position CVR to be an emerging player within the healthcare sector it is critical that we educate the marketplace about how our organization is working to address unmet medical needs in the management of cardiovascular disease. ICR Healthcare’s team will help us communicate the unique value proposition of CVR, allowing us to differentiate ourselves in a competitive environment and pave the way for the anticipated commercial introduction of our CSS device.”

 About CVR Medical

CVR Medical is a company involved and operates in the medical industry that focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology (CSS) and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

For further information contact:

Peter Bakema, CEO, President and Director
Telephone: (734) 718-5115
Email: info@cvrmed.com

Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888

Marc S. Lubow.
Vice President Capital Markets, Investor Relations
marclubow@cvrmed.com
Telephone: (904) 923 – 4037


 

This press release contains forward-looking statements or information (collectively referred to herein as “forward-looking statements”) that involves various risks and uncertainties regarding future events related to the Joint Venture and the Transaction.  Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company.  In this press release such statements include but are not limited to the completion of the Transaction and the associated regulatory and shareholder approval requirements. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

 

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.